Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

This study has been completed.
Celgene Corporation
Information provided by (Responsible Party):
Luciano J. Costa, Medical University of South Carolina Identifier:
First received: May 4, 2010
Last updated: June 18, 2013
Last verified: July 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)